Skip to main content
. 2020 Jan 28;7(2):645–653. doi: 10.1002/ehf2.12624

Figure 3.

Figure 3

Left ventricular end systolic volume (LVESV) and left ventricular ejection fraction (LVEF) response in the total population, non‐ischaemic dilated cardiomyopathy, and ischaemic cardiomyopathy patients. Upper row, long‐term outcome according to LVESV response; and lower row, long‐term outcome according to LVEF response. Bold line = responders and dashed line = non‐responders. Model 1, age and sex; and model 2, age, sex, device type, estimated glomerular filtration rate, (history of) atrial fibrillation, LVESV at baseline, LVEF at baseline, N terminal pro brain natriuretic peptide, β‐blocker use, angiotensin converting enzyme inhibitors/angiotensin‐receptor blockers use, and diuretic use. HR, hazard ratio; ICM, ischaemic cardiomyopathy; LVEF, left ventricular ejection fraction; LVESV, left ventricular end systolic volume; NIDCM, non‐ischaemic dilated cardiomyopathy.